<html><head>
	<title>navb20231222_s8.htm</title>

	<!-- Generated by ThunderDome Portal - 12/23/2023 12:22:12 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>As filed with the Securities and Exchange Commission on</b>&nbsp;<b>December 22, 2023</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No.</b>&nbsp;<b>333-[_____]</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#8203;FORM S-8</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNDER</b><br>
<b>THE SECURITIES ACT OF 1933</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>NAVIDEA BIOPHARMACEUTICALS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b>&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#8203;&#8203;2835 </b></p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>31-1080091</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of<br>
			Incorporation or Organization)</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Primary Standard Industrial</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Classification Code Number)</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4995 Bradenton Avenue, Suite 240</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dublin, Ohio 43017</b><br>
<b>(614) 793-7500</b><br>
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Navidea Biopharmaceuticals, Inc. 2023 Equity Incentive Plan</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Full title of plan)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Craig A. Dais</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Financial Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Navidea Biopharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4995 Bradenton Avenue, Suite 240</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dublin, Ohio 43017</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(614) 793-7500</b><br>
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Copies to:</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>William M. Mower, Esq.</b><br>
<b>Maslon LLP</b><br>
<b>90 South 7</b><b><sup style="vertical-align:top;line-height:120%;">th</sup></b><b> Street, Suite 3300</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Minneapolis, MN 55402</b>&#8203;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Non-accelerated filer&nbsp;&nbsp;&#9746;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company &#9746;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Emerging growth company &#9744;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1). Such documents are not being filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act of 1933.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 3.</b>&nbsp;<b>Incorporation of Documents by Reference.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company incorporates by reference into this Registration Statement the following documents that the Company has previously filed with the SEC:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923008054/navb20221231_10k.htm" style="-sec-extract:exhibit;">March 27, 2023</a>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923013972/navb20230331_10q.htm" style="-sec-extract:exhibit;">May 11, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923023319/navb20230630_10q.htm" style="-sec-extract:exhibit;">August 11, 2023</a>, and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923032052/navb20230930_10q.htm" style="-sec-extract:exhibit;">November 14, 2023</a>, respectively;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current Reports on Form 8-K and all amendments thereto on Form 8-K/A, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923000803/navb20230110_8k.htm" style="-sec-extract:exhibit;">January 10, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923006915/navb20230316_8k.htm" style="-sec-extract:exhibit;">March 16, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923007389/navb20230321_8k.htm" style="-sec-extract:exhibit;">March 21, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923008884/navb20230331_8k.htm" style="-sec-extract:exhibit;">March 31, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923010201/navb20230412_8k.htm" style="-sec-extract:exhibit;">April 13, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923011528/navb20230427_8k.htm" style="-sec-extract:exhibit;">April 28, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923015848/navb20230525_8k.htm" style="-sec-extract:exhibit;">May 25, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923016520/navb20230602_8k.htm" style="-sec-extract:exhibit;">June 5, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923017745/navb20230615_8k.htm" style="-sec-extract:exhibit;">June 16, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923019502/navb20230705_8k.htm" style="-sec-extract:exhibit;">July 6, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923019901/navb20230713_8k.htm" style="-sec-extract:exhibit;">July 13, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923021059/navb20230728_8k.htm" style="-sec-extract:exhibit;">July 28, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923022524/navb20230808_8k.htm" style="-sec-extract:exhibit;">August 8, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923032354/navb20231116_8k.htm" style="-sec-extract:exhibit;">November 16, 2023</a>, and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774923033343/navb20231130_8k.htm" style="-sec-extract:exhibit;">December 1, 2023</a>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Definitive Proxy Statement filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/810509/000143774923027767/navb20231003_def14a.htm" style="-sec-extract:exhibit;">October 5, 2023</a>; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The description of the Company&#8217;s common stock which is contained in Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/810509/000143774920005567/ex_176385.htm" style="-sec-extract:exhibit;">March 18, 2020</a>, including all amendments and reports filed for the purpose of updating such description.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 4.</b>&nbsp;<b>Description of Securities. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 5.</b>&nbsp;<b>Interests of Named Experts and Counsel. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 6.</b>&nbsp;<b>Indemnification of Directors and Officers. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Section 145 of the General Corporation Law of the State of Delaware (Section 145) provides that directors and officers of Delaware corporations may, under certain circumstances, be indemnified against expenses (including attorneys&#8217; fees) and other liabilities actually and reasonably incurred by them as a result of any suit brought against them in their capacity as a director or officer, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. Section 145 also provides that directors and officers may also be indemnified against expenses (including attorneys&#8217; fees) incurred by them in connection with a derivative suit if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification may be made without court approval if such person was adjudged liable to the corporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Article Five of the Company&#8217;s bylaws contains provisions which require that the Company indemnify its officers, directors, employees and agents, in substantially the same language as Section 145.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Article Nine, section (b), of the Company&#8217;s certificate of incorporation further provides that no director will be personally liable to the Company or its stockholders for monetary damages or for any breach of fiduciary duty except for breach of the director&#8217;s duty of loyalty to the Company or its stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, pursuant to Section 174 of the Delaware General Corporation Law (which imposes liability in connection with the payment of certain unlawful dividends, stock purchases or redemptions), or any amendment or successor provision thereto, or for any transaction from which a director derived an improper personal benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.</b>&nbsp;<b>Exemption from Registration Claimed. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.</b>&nbsp;<b>Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit Number</b></p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:34pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">&nbsp;&nbsp;5.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_609875.htm" style="-sec-extract:exhibit;">Opinion of Maslon LLP regarding legality.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/810509/000143774923032354/ex_598122.htm" style="-sec-extract:exhibit;">Navidea Biopharmaceuticals, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed November 16, 2023).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">23.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_609875.htm" style="-sec-extract:exhibit;">Consent of Maslon LLP (included in Exhibit 5.1).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">23.2</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_609877.htm" style="-sec-extract:exhibit;">Consent of Marcum LLP.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">24.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Powers of Attorney (included on signature page hereto).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">107</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_609741.htm" style="-sec-extract:exhibit;">Calculation of Filing Fee Table</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signatures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, State of Ohio, on December 22, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NAVIDEA BIOPHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.4%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>/s/ Craig A. Davis</i></p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Craig A. Davis</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" name="poa" title="poa"></a>POWER OF ATTORNEY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each person whose signature appears below constitutes and appoints Craig A. Davis as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13.9%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Craig A. Davis</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Craig A. Davis</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">(<i>Principal Financial Officer and </i></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Principal Accounting Officer</i>)</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13.9%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ John K. Scott, Jr.</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-1pt;">Vice Chair of the Board of Directors (<i>Principal Executive Officer</i>)</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">John K. Scott, Jr.</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Dana Moss</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Dana Moss, JD</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Joshua M. Wilson</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Joshua M. Wilson</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Jill Bieker Stefanelli</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Jill Bieker Stefanelli, Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
[{"type": "S-8", "sequence": "1", "filename": "navb20231222_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 43480}]
{"company-data": {"conformed-name": "NAVIDEA BIOPHARMACEUTICALS, INC.", "cik": "0000810509", "assigned-sic": "2835", "organization-name": "03 Life Sciences", "irs-number": "311080091", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-276266", "film-number": "231511152"}, "business-address": {"street1": "4995 BRADENTON AVENUE", "street2": "SUITE 240", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147937500"}, "mail-address": {"street1": "4995 BRADENTON AVENUE", "street2": "SUITE 240", "city": "DUBLIN", "state": "OH", "zip": "43017"}, "former-company": {"former-conformed-name": "NEOPROBE CORP", "date-changed": "19940714"}}
navb20231222_s8.htm
As filed with the Securities and Exchange Commission on
December 22, 2023
Registration No.
333-[_____]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
​FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NAVIDEA BIOPHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
​
Delaware
​​2835
31-1080091
​
​
(State or Other Jurisdiction of
Incorporation or Organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
​
4995 Bradenton Avenue, Suite 240
Dublin, Ohio 43017
(614) 793-7500
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Navidea Biopharmaceuticals, Inc. 2023 Equity Incentive Plan
(Full title of plan)
Craig A. Dais
Chief Financial Officer
Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue, Suite 240
Dublin, Ohio 43017
(614) 793-7500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
William M. Mower, Esq.
Maslon LLP
90 South 7
th
Street, Suite 3300
Minneapolis, MN 55402
​
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer  ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1). Such documents are not being filed with the Securities and Exchange Commission (the "Commission") either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act of 1933.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The Company incorporates by reference into this Registration Statement the following documents that the Company has previously filed with the SEC:
●
Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on
March 27, 2023
;
●
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, filed with the SEC on
May 11, 2023
,
August 11, 2023
, and
November 14, 2023
, respectively;
●
Current Reports on Form 8-K and all amendments thereto on Form 8-K/A, filed with the SEC on
January 10, 2023
,
March 16, 2023
,
March 21, 2023
,
March 31, 2023
,
April 13, 2023
,
April 28, 2023
,
May 25, 2023
,
June 5, 2023
,
June 16, 2023
,
July 6, 2023
,
July 13, 2023
,
July 28, 2023
,
August 8, 2023
,
November 16, 2023
, and
December 1, 2023
;
●
Definitive Proxy Statement filed with the SEC on
October 5, 2023
; and
●
The description of the Company's common stock which is contained in Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on
March 18, 2020
, including all amendments and reports filed for the purpose of updating such description.
All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Section 145 of the General Corporation Law of the State of Delaware (Section 145) provides that directors and officers of Delaware corporations may, under certain circumstances, be indemnified against expenses (including attorneys' fees) and other liabilities actually and reasonably incurred by them as a result of any suit brought against them in their capacity as a director or officer, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. Section 145 also provides that directors and officers may also be indemnified against expenses (including attorneys' fees) incurred by them in connection with a derivative suit if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification may be made without court approval if such person was adjudged liable to the corporation.
Article Five of the Company's bylaws contains provisions which require that the Company indemnify its officers, directors, employees and agents, in substantially the same language as Section 145.
Article Nine, section (b), of the Company's certificate of incorporation further provides that no director will be personally liable to the Company or its stockholders for monetary damages or for any breach of fiduciary duty except for breach of the director's duty of loyalty to the Company or its stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, pursuant to Section 174 of the Delaware General Corporation Law (which imposes liability in connection with the payment of certain unlawful dividends, stock purchases or redemptions), or any amendment or successor provision thereto, or for any transaction from which a director derived an improper personal benefit.
3
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits
Exhibit Number
Description
5.1
Opinion of Maslon LLP regarding legality.
10.1
Navidea Biopharmaceuticals, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed November 16, 2023).
23.1
Consent of Maslon LLP (included in Exhibit 5.1).
23.2
Consent of Marcum LLP.
24.1
Powers of Attorney (included on signature page hereto).
107
Calculation of Filing Fee Table
4
Signatures
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, State of Ohio, on December 22, 2023.
NAVIDEA BIOPHARMACEUTICALS, INC.
/s/ Craig A. Davis
Craig A. Davis
Chief Financial Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Craig A. Davis as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature
Title
Date
/s/ Craig A. Davis
Chief Financial Officer
December 22, 2023
Craig A. Davis
(
Principal Financial Officer and
Principal Accounting Officer
)
/s/ John K. Scott, Jr.
Vice Chair of the Board of Directors (
Principal Executive Officer
)
December 22, 2023
John K. Scott, Jr.
/s/ Dana Moss
Director
December 22, 2023
Dana Moss, JD
/s/ Joshua M. Wilson
Director
December 22, 2023
Joshua M. Wilson
/s/ Jill Bieker Stefanelli
Director
December 22, 2023
Jill Bieker Stefanelli, Ph.D.